News and Trends 3 Aug 2018 Precision Antibiotic Improves Outcome of Gut Infections in Phase II Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more effective in reducing the recurrence of the disease than the standard of care. Clostridium difficile is a bacterium that can infect the gut after a patient receives broad spectrum antibiotics. C. difficile infections typically cause diarrhoea and abdominal pain, but […] August 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 3 Aug 2018 This Biotech Targets the Neuronal Causes of Hearing Loss Today, we’re in Archamps, France, visiting Pragma Therapeutics, a neuroscience biotech developing drugs to regulate neuronal signalling in hearing loss. Mission: Pragma Therapeutics develops treatments for noise-induced and age-related hearing loss that regulate glutamate levels. Glutamate is the most abundant neurotransmitter in the nervous system and makes nerve cells turn on, or fire. In patients with […] August 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 2 Aug 2018 Tomato DNA Could Help Uncover Counterfeit Breast Implants Counterfeit breast implants can harm patients’ health and even threaten their lives. A German research team is using tomato DNA tags to tell the ‘real thing’ apart from frauds. The silicone used in implants need to have a high-quality to prevent silicone from leaking out of the implant. As a result, the silicone used in […] August 2, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2018 EMA Temporarily Scales Back Activities to Prepare for Brexit As a result of Brexit, the European Medicines Agency will suspend some of its activities to prepare for staff cuts and its move from London to Amsterdam next year. As of October 1st, the EMA will cut back on international collaborations, developing guidelines for regulatory approval, and publishing clinical data in order to maintain its […] August 2, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2018 Recycled Forestry Waste Could Make Cosmetics, Plastics and Biofuel An EU project is using forestry waste to make 2,3-butanediol, a chemical with a wide range of industrial applications, from perfumes to synthetic rubber and food additives. Rehap, an EU project, has found a way to produce 2,3-butanediol, a chemical building block used in a range of industrial applications, using sugars purified from forestry waste. […] July 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2018 Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results RedHill Biopharma has obtained positive Phase III results for its Crohn’s disease treatment, which targets a certain type of gut bacteria. Crohn’s disease is a type of inflammatory bowel disease, characterized by acute flare-ups and periods of symptom-free remission, that can affect any part of the gastrointestinal tract. It has a high prevalence for an autoimmune disease, […] July 31, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 30 Jul 2018 We May Soon Diagnose Traumatic Brain Injury With a Single Drop of Blood Swiss and Spanish researchers are developing a diagnostic test that measures the severity of mild traumatic brain injury that delivers results in ten minutes with a single drop of blood. CT scans are currently the only reliable method for diagnosing mild traumatic brain injury. However, the technology is not available in all hospitals, is expensive […] July 30, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2018 Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […] July 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2018 Austrian Researchers Grow Cancerous Mini Brains in a Dish Researchers in Vienna are growing mini brains that mimic the onset and development of brain cancer, which could be used to compare the efficacy of different treatments. Because of their cellular complexity, brain cancers have been difficult to study in animals. Glioblastoma, the most aggressive form of brain cancer, is particularly difficult to treat because […] July 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jul 2018 Celyad’s Donor Cell CAR-T Therapy Gets Closer to the Clinic Celyad has received FDA approval to start clinical trials for its CAR-T cell therapy, which is engineered to avoid side effects associated with using donor cells for this kind of treatment. The Belgian biotech has been cleared to test its CAR-T cell therapy, made from donor cells, in patients with unresectable colorectal cancer in combination […] July 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2018 UK Biotech to Launch Rapid, Accurate HIV Test in Europe UK-biotech Owen Mumford plans to launch an HIV diagnostic test in Europe that can produce an accurate result within 15 minutes. Current rapid diagnostic tests for HIV can lead to misdiagnosis, for example when steps in the procedure are not followed in the right order, or too little blood is drawn. The new test, called […] July 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2018 Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […] July 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email